லாரஸ் உயிர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from லாரஸ் உயிர். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In லாரஸ் உயிர் Today - Breaking & Trending Today
Laurus Labs registers revenue growth of 31 per cent at Rs 1,279 Cr biospectrumindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospectrumindia.com Daily Mail and Mail on Sunday newspapers.
Laurus Labs registers revenue growth of 31 per cent at Rs 1,279 Cr biospectrumindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospectrumindia.com Daily Mail and Mail on Sunday newspapers.
Read more about Laurus Labs rallies 5% on credit rating upgrade; stock hits record high on Business Standard. The company is looking to build new capacities/facilities that would propel its growth in the coming years ....
Shares of Laurus Labs moved higher by 5 per cent to Rs 474.95 on the BSE in intra-day trade on Monday, erasing a 4.5 per cent fall witnessed in the past two trading days, on a strong growth outlook. The stock of the pharmaceutical company hit a record high of Rs 482.65 on April 29, the day on which the company announced its January-March quarter (Q4FY21) earnings. The company’s Q4 revenues grew 68.3 per cent year-on-year (YoY) to Rs 1,412 crore with strong growth across segments. Earnings before interest, taxes, depreciation and amortization (Ebitda) margins improved 1,059 basis points (bps) to 33.4 per cent against 22.9 per cent in Q4FY20 due to better product mix and improved operating leverage. Subsequently, Ebitda grew 146 per cent YoY to Rs 472 crore. The profit after tax (PAT) was up 169 per cent YoY at Rs 297 crore, in line with a strong operational performance. ....
Laurus Labs net surges on higher sales Updated: Updated: Share Article AAA Drugmaker Laurus Labs has reported a consolidated net profit of ₹297 crore for the quarter ended March on the back of good show in key business segments. The drugmaker had posted a net profit of ₹110.15 crore in the same period last fiscal. Revenue from operations increased to ₹1,412 crore (₹839.14 crore). For the full fiscal, net profit stood at ₹984 crore (₹255.27 crore), while revenue from operations was ₹4,814 crore (₹2,831.72 crore). The company has declared an interim dividend of 80 paise (40%) per equity share of ₹2 each Founder and CEO Satyanarayana Chava said the company delivered a strong performance in all divisions and remained confident of strengthening it further in FY22. The increase in sales was ₹1,981 crore in the fiscal. With acquisition of majority stake in Richcore Life Sciences (renamed as Laurus Bio), Laurus Labs has entered into the hig ....